Healthcare resource utilization, costs and treatment associated with myasthenia gravis exacerbations among patients with myasthenia gravis in the USA: a retrospective analysis of claims data
Conclusion: Despite utilization of current treatments for MG, MG exacerbations are associated with a high clinical and economic burden in both commercial and Medicare patients. Additional treatment options and improved disease management may help to reduce exacerbations and disease burden.PMID:38099519 | DOI:10.57264/cer-2023-0108 (Source: Journal of Comparative Effectiveness Research)
Source: Journal of Comparative Effectiveness Research - December 15, 2023 Category: General Medicine Authors: Julia Pisc Angela Ting Michelle Skornicki Omar Sinno Edward Lee Source Type: research

Treatment patterns and economic burden of bacterial vaginosis among commercially insured women in the USA
Conclusion: BV recurrence among this population represented a substantial clinical and healthcare economic burden warranting improvements in women's healthcare.PMID:38099520 | DOI:10.57264/cer-2023-0079 (Source: Journal of Comparative Effectiveness Research)
Source: Journal of Comparative Effectiveness Research - December 15, 2023 Category: General Medicine Authors: Eren Watkins Clifton M Chow Melissa Lingohr-Smith Jay Lin Candice Yong Krishna Tangirala Kevin Collins James Li Roy Brooks Jennifer Amico Source Type: research

Improved estimation of overall survival and progression-free survival for state transition modeling
Conclusion: A novel approach is defined which provides an alternative STM estimation method enabling improved fits to modeled endpoints, which can easily be extended to more complex model structures.PMID:38099516 | DOI:10.57264/cer-2023-0031 (Source: Journal of Comparative Effectiveness Research)
Source: Journal of Comparative Effectiveness Research - December 15, 2023 Category: General Medicine Authors: Peter C Wigfield Bart Heeg Mario Ouwens Source Type: research

Real-world use of inotuzumab ozogamicin is associated with lower health care costs than blinatumomab in patients with acute lymphoblastic leukemia in the first relapsed/refractory setting
Conclusion: In the first R/R setting, patients who used InO had significantly lower all-cause and ALL-related costs compared with patients who used Blina, in part driven by hospitalization patterns.PMID:38099517 | DOI:10.57264/cer-2023-0142 (Source: Journal of Comparative Effectiveness Research)
Source: Journal of Comparative Effectiveness Research - December 15, 2023 Category: General Medicine Authors: Alexander Russell-Smith Louise Murphy Amy Nguyen Cori Blauer-Peterson Marilou Terpenning Feng Cao Shiqiang Li Tim Bancroft Noah Webb Stephanie Dorman Richa Shah Source Type: research

Risk of long-term care admissions among Medicare beneficiaries treated with pimavanserin or quetiapine for Parkinson's disease psychosis in USA: a retrospective administrative claims database analysis
Conclusion: The 20% lower risk of LTCA (i.e., greater delay) with PIM versus QUE in this analysis may suggest that PIM should be started early for the treatment of PDP.PMID:38099518 | DOI:10.57264/cer-2023-0114 (Source: Journal of Comparative Effectiveness Research)
Source: Journal of Comparative Effectiveness Research - December 15, 2023 Category: General Medicine Authors: Krithika Rajagopalan Nazia Rashid Dilesh Doshi Source Type: research

Healthcare resource utilization, costs and treatment associated with myasthenia gravis exacerbations among patients with myasthenia gravis in the USA: a retrospective analysis of claims data
Conclusion: Despite utilization of current treatments for MG, MG exacerbations are associated with a high clinical and economic burden in both commercial and Medicare patients. Additional treatment options and improved disease management may help to reduce exacerbations and disease burden.PMID:38099519 | DOI:10.57264/cer-2023-0108 (Source: Journal of Comparative Effectiveness Research)
Source: Journal of Comparative Effectiveness Research - December 15, 2023 Category: General Medicine Authors: Julia Pisc Angela Ting Michelle Skornicki Omar Sinno Edward Lee Source Type: research

Treatment patterns and economic burden of bacterial vaginosis among commercially insured women in the USA
Conclusion: BV recurrence among this population represented a substantial clinical and healthcare economic burden warranting improvements in women's healthcare.PMID:38099520 | DOI:10.57264/cer-2023-0079 (Source: Journal of Comparative Effectiveness Research)
Source: Journal of Comparative Effectiveness Research - December 15, 2023 Category: General Medicine Authors: Eren Watkins Clifton M Chow Melissa Lingohr-Smith Jay Lin Candice Yong Krishna Tangirala Kevin Collins James Li Roy Brooks Jennifer Amico Source Type: research

Improved estimation of overall survival and progression-free survival for state transition modeling
Conclusion: A novel approach is defined which provides an alternative STM estimation method enabling improved fits to modeled endpoints, which can easily be extended to more complex model structures.PMID:38099516 | DOI:10.57264/cer-2023-0031 (Source: Journal of Comparative Effectiveness Research)
Source: Journal of Comparative Effectiveness Research - December 15, 2023 Category: General Medicine Authors: Peter C Wigfield Bart Heeg Mario Ouwens Source Type: research

Real-world use of inotuzumab ozogamicin is associated with lower health care costs than blinatumomab in patients with acute lymphoblastic leukemia in the first relapsed/refractory setting
Conclusion: In the first R/R setting, patients who used InO had significantly lower all-cause and ALL-related costs compared with patients who used Blina, in part driven by hospitalization patterns.PMID:38099517 | DOI:10.57264/cer-2023-0142 (Source: Journal of Comparative Effectiveness Research)
Source: Journal of Comparative Effectiveness Research - December 15, 2023 Category: General Medicine Authors: Alexander Russell-Smith Louise Murphy Amy Nguyen Cori Blauer-Peterson Marilou Terpenning Feng Cao Shiqiang Li Tim Bancroft Noah Webb Stephanie Dorman Richa Shah Source Type: research

Risk of long-term care admissions among Medicare beneficiaries treated with pimavanserin or quetiapine for Parkinson's disease psychosis in USA: a retrospective administrative claims database analysis
Conclusion: The 20% lower risk of LTCA (i.e., greater delay) with PIM versus QUE in this analysis may suggest that PIM should be started early for the treatment of PDP.PMID:38099518 | DOI:10.57264/cer-2023-0114 (Source: Journal of Comparative Effectiveness Research)
Source: Journal of Comparative Effectiveness Research - December 15, 2023 Category: General Medicine Authors: Krithika Rajagopalan Nazia Rashid Dilesh Doshi Source Type: research

Healthcare resource utilization, costs and treatment associated with myasthenia gravis exacerbations among patients with myasthenia gravis in the USA: a retrospective analysis of claims data
Conclusion: Despite utilization of current treatments for MG, MG exacerbations are associated with a high clinical and economic burden in both commercial and Medicare patients. Additional treatment options and improved disease management may help to reduce exacerbations and disease burden.PMID:38099519 | DOI:10.57264/cer-2023-0108 (Source: Journal of Comparative Effectiveness Research)
Source: Journal of Comparative Effectiveness Research - December 15, 2023 Category: General Medicine Authors: Julia Pisc Angela Ting Michelle Skornicki Omar Sinno Edward Lee Source Type: research

Treatment patterns and economic burden of bacterial vaginosis among commercially insured women in the USA
Conclusion: BV recurrence among this population represented a substantial clinical and healthcare economic burden warranting improvements in women's healthcare.PMID:38099520 | DOI:10.57264/cer-2023-0079 (Source: Journal of Comparative Effectiveness Research)
Source: Journal of Comparative Effectiveness Research - December 15, 2023 Category: General Medicine Authors: Eren Watkins Clifton M Chow Melissa Lingohr-Smith Jay Lin Candice Yong Krishna Tangirala Kevin Collins James Li Roy Brooks Jennifer Amico Source Type: research

Improved estimation of overall survival and progression-free survival for state transition modeling
Conclusion: A novel approach is defined which provides an alternative STM estimation method enabling improved fits to modeled endpoints, which can easily be extended to more complex model structures.PMID:38099516 | DOI:10.57264/cer-2023-0031 (Source: Journal of Comparative Effectiveness Research)
Source: Journal of Comparative Effectiveness Research - December 15, 2023 Category: General Medicine Authors: Peter C Wigfield Bart Heeg Mario Ouwens Source Type: research

Real-world use of inotuzumab ozogamicin is associated with lower health care costs than blinatumomab in patients with acute lymphoblastic leukemia in the first relapsed/refractory setting
Conclusion: In the first R/R setting, patients who used InO had significantly lower all-cause and ALL-related costs compared with patients who used Blina, in part driven by hospitalization patterns.PMID:38099517 | DOI:10.57264/cer-2023-0142 (Source: Journal of Comparative Effectiveness Research)
Source: Journal of Comparative Effectiveness Research - December 15, 2023 Category: General Medicine Authors: Alexander Russell-Smith Louise Murphy Amy Nguyen Cori Blauer-Peterson Marilou Terpenning Feng Cao Shiqiang Li Tim Bancroft Noah Webb Stephanie Dorman Richa Shah Source Type: research

Risk of long-term care admissions among Medicare beneficiaries treated with pimavanserin or quetiapine for Parkinson's disease psychosis in USA: a retrospective administrative claims database analysis
Conclusion: The 20% lower risk of LTCA (i.e., greater delay) with PIM versus QUE in this analysis may suggest that PIM should be started early for the treatment of PDP.PMID:38099518 | DOI:10.57264/cer-2023-0114 (Source: Journal of Comparative Effectiveness Research)
Source: Journal of Comparative Effectiveness Research - December 15, 2023 Category: General Medicine Authors: Krithika Rajagopalan Nazia Rashid Dilesh Doshi Source Type: research